Disclaimer

Disclaimer and copyright notice

Disclaimer notice

This website contains certain statements that are not historical facts and may be forward-looking statements that are subject to a variety of risks and uncertainties. There are a number of important factors that could cause actual results to differ materially from those projected or suggested in any forward-looking statement made by ImmuPharma plc (“the company”).

These factors include, but are not limited to: (i) the company’s and/or the company’s partners’ ability to complete successfully product research and development, including pre-clinical and clinical studies and commercialisation; (ii) the company’s and/or the company’s partners’ ability to obtain required governmental approvals, including product and patent approvals, the impact of pharmaceutical industry regulation, the difficulty of predicting FDA and other regulatory authority approvals, the regulatory environment and changes in the health policies and structure of various countries; (iii) the acceptance and demand for new pharmaceutical products and new discovery-enabling technologies such as the use of cells and the company’s ability to attract and/or maintain manufacturing, sales, distribution and marketing partners; and (iv) the company’s and/or the company’s partners’ ability to develop and commercialise products before its competitors and the impact of competitive products and pricing, the availability and pricing of ingredients used in the manufacture of products, uncertainties regarding market acceptance of innovative products newly launched, currently being sold or in development.

In addition, significant fluctuations in financial results may occur as a result of the timing of milestone payments and the timing of costs and expenses related to the company’s research and development programme.

Without limiting the generality of the foregoing, no assurance is given as to when the company’s products will be launched or whether that launch will be commercially successful, and words such as “may”, “will”, “to”, “expect”, “plan”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate”, or “continue” or the negative or other variations thereof or comparable terminology is intended to identify forward-looking statements. Investors are cautioned that all forward-looking statements involve risks and uncertainties.

The company, its subsidiaries, directors, officers, associates or advisers shall under no circumstance be liable to investors or any other third party for any lost profits or lost opportunity, indirect, incidental, consequential, special, or punitive damages whatsoever.

Copyright notice

The content of this website, including but not limited to all design, text and other information, is owned by the company and may not be reproduced, transmitted, displayed, distributed or commercially exploited in any respect and may not be copied without express written permission from the company, except that one copy, electronic or mechanical may be used by the viewer for personal and non commercial reference use only, provided it is kept together with a copy of all notices and disclaimer herein. The use or misuse of any of the materials, drawings and symbols contained in this website is expressly prohibited and may be in violation of appropriate laws. The company will actively enforce its intellectual property rights to the fullest extent of the law.

Unless a confidential disclosure agreement has been entered into between the company and the party supplying the information, any information sent to this internet site or to the company by any person shall be deemed non-confidential and no obligation or responsibility is accepted in relation thereto. The company shall be free to use, publish, reproduce and disclose such information as it sees fit for any purpose whatsoever.

You may only provide a hypertext link to this website provided that the link must be clearly marked “ImmuPharma” and point to the URL http://www.immupharma.com/ and not to other pages within the company’s website. Links provided from this website to other web pages over which the company has no control, are so provided for convenience only and as such, the company neither endorses nor makes any representations as to the accuracy or any other aspect of the information contained in such other web pages.

The terms of this Disclaimer and copyright notice may only be amended by the company and are governed by the laws of England.

US Persons

Special rules apply when US persons (as defined in the United States securities laws) access this website.

NO SHARES OR OTHER SECURITIES OF IMMUPHARMA PLC OR ANY OF ITS SUBSIDIARIES HAVE BEEN OR WILL BE REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED, (“THE SECURITIES ACT”) OR UNDER THE SECURITIES LEGISLATION OF ANY STATE OF THE UNITED STATES OR ANY PROVINCE OR TERRITORY OF CANADA AND SUCH SHARES OR OTHER SECURITIES MAY NOT BE OFFERED, SOLD, DELIVERED, ASSIGNED OR TRANSFERRED, DIRECTLY OR INDIRECTLY, WITHIN THE UNITED STATES OR CANADA OR TO OR FOR THE BENEFIT OF ANY PERSON WHO IS A RESIDENT OF THE UNITED STATES OR CANADA (INCLUDING CORPORATIONS, PARTNERSHIPS OR OTHER ENTITIES CREATED OR ORGANISED IN OR UNDER THE LAWS OF THE UNITED STATES OR CANADA OR ANY ESTATE OR TRUST WHICH IS SUBJECT TO UNITED STATES FEDERAL OR CANADIAN INCOME TAXATION REGARDLESS OF THE SOURCE OF ITS INCOME), “UNITED STATES” MEANS THE UNITED STATES OF AMERICA, EACH STATE THEREOF AND THE DISTRICT OF COLUMBIA, ITS TERRITORIES AND POSSESSIONS AND OTHER AREAS SUBJECT TO ITS JURISDICTION AND “CANADA” INCLUDES ITS POSSESSIONS AND TERRITORIES.

For US regulatory reasons, US residents and other US persons who reside outside the United States are not permitted to access this website. The company is not offering any securities or services in the United States or to residents of the United States through this website or otherwise. The information contained on this website is not an offer to sell or a solicitation of an offer to buy the securities of the company within or outside the United States. No money, securities or other consideration is being solicited by making information available on this website and, if money is sent in response to the information on the website, it will not be accepted. A “US Person” includes any US person, as well as (i) any natural person who is only temporarily residing outside the United States, (ii) any account of a US Person over which a non-US fiduciary has investment discretion or any entity, which, in either case, is being used to circumvent the registration requirements of the US Investment Company Act of 1940, and (iii) any employee benefit or pension plan that does not have as its participants or beneficiaries persons substantially all of whom are not US persons. In addition, for these purposes, if an entity either has been formed or is operated for the purpose of investing in a particular security or obtaining a particular service, or facilitates individual investment decisions, none of the beneficiaries or other interest holders of such entity may be US Residents. Terms used in this paragraph (including the term “US Person”) have the meanings given to them in Regulation S under the Securities Act.

Lisa Baderoon

Non-Executive Director and Head of Investor Relations

Lisa has spent over 25 years working within the City of London being involved with a diverse portfolio of clients from a variety of sectors but with a leaning towards emerging, high growth businesses advising both private and public companies on their financial and corporate strategies aligned to stakeholder and investor interests, as well as a strong acumen in media communication. During this time, she has been involved in a multitude of client transactions spanning private fund raisings, Initial Public Offerings (IPOs), secondary high profile capital raisings and mergers and acquisitions both in the UK and internationally.

Lisa had a successful career spanning 20 years as a Partner at Buchanan Communications, one of the leading City financial public relations agencies. As one of the youngest Board members, she was involved in the successful five-year earnout, as part of Buchanan being acquired by the FTSE 100 rated WPP Plc in 1997.

Lisa founded Just B Communications Ltd in 2012 with the key objective of working with a more select number of clients and providing a greater degree of bespoke advisory services thus becoming more integral to the day to day corporate and strategic development for these businesses. She has successfully advised a number of public and private companies, at Board level, on corporate strategy, stakeholder and investor communications, capital raisings, dual listings, licensing and M&A. Media profiling, where required, has also played an important role in advisory activities.

Lisa was appointed Head of Investor Relations at ImmuPharma in 2012 and most recently appointed as a Non-Executive Director in July 2021.

Ketan Patel

Independent Non-Executive Director

Ketan is an experienced investment professional who brings extensive expertise in financial markets, with a particular focus on the UK healthcare and life science sectors. He has been a long-term investor in UK markets, working as both an analyst and Fund Manager, managing institutional, retail, and charity mandates. Ketan began his career at JP Morgan before moving to Insight Investment, where he served as a global Pharmaceutical and Healthcare analyst. He then spent over 20 years at EdenTree Investment Management, where he was responsible for UK equity and global equity income strategies, consistently delivering upper-quartile performance.

Ketan combines rigorous fundamental analysis with risk-focused investment strategies. He is also a published thought leader on sustainability and investment themes. Ketan is a CFA Charterholder and holds an MSc in Economic History from the London School of Economics, an MSc in Geography from King’s College London, and a BA (Hons) in History and Geography from Queen Mary University, London.

Dr Laurence Reilly MBA

Senior Independent Non-Executive Director

Dr Laurence Reilly has been appointed as Senior independent Non-Executive Director and Chair of the Audit Committee. Dr Reilly brings extensive experience in managing late-stage clinical programs through to approval, in addition to commercial and business development experience.

He is currently Vice President of Research & Investments, working with Royalty Pharma, a New York based life science investment company focussing on acquisition of biopharmaceutical royalties and funding of innovation across the biopharmaceutical industry.

Through his consulting practice (Acumen Life Science Investment Consulting) Dr Reilly has provided strategic consulting and due-diligence services to biotech companies, life science venture capital and private equity clients. He also served as Chief Medical Officer for Cellectar Biosciences, New Jersey, a late-stage oncology biotech company. Prior to founding his consulting practice, Dr Reilly served as Chief Scientific Officer and Vice President at Avillion, a drug development company focused on the co-development and financing of drug candidates, where he was responsible for clinical and strategic oversight of co-development programs and partnering with both large pharma and biotech, including Pfizer, Merck KGaA and AstraZeneca. Dr. Reilly previously served as a Clinician – Clinical Development & Medical Oversight at Pfizer and at Lundbeck as Medical & Scientific Advisor.

Dr Reilly earned his medical degree from the University of Liverpool Medical School, U.K., and practiced as Neurosurgery Resident at Queen Elizabeth University Hospital in Birmingham. Dr Reilly also holds a Masters Degree in Law from De Montfort University, U.K.

Dr Tim Franklin PhD, MBA

Chief Operating Officer

Tim has 30 years’ experience in the biopharmaceutical industry. He worked in clinical research, sales & marketing, and global strategic marketing for Warner Lambert, Wellcome and SmithKline Beecham. He later moved to the capital markets where he became a top-ranked pharmaceuticals analyst at Dresdner Kleinwort investment bank. He applied his experience to stock selection at hedge funds and advised several small biotechnology companies on corporate and commercial strategy and access to capital. He holds a BSc in Medicinal Chemistry and a PhD in Pharmacology from Loughborough University and an MBA from Warwick Business School.

Dr Laura Mauran-Ambrosino Ph.D.

Head of R&D

Born in Montpellier, France, Dr Mauran- Ambrosino obtained her PhD in Chemistry at the Université de Bordeaux as a CIFRE fellow in co-supervision by Dr Goudreau.

She then conducted postdoctoral studies at the “Centre Hospitalier Universitaire” Pellegrin in cell biology. In 2018, she joined Ureka and established the biology department and the analytical chemistry department and in 2021, she became Chief Scientific Officer of Ureka Pharma. Dr Mauran-Ambrosino was a key contributor to the development of BioGlucagon, and BioAMB.

Ashley Clarke ACA

Chief Financial Officer & Company Secretary

Ashley brings over a decade of experience in the financial sector. She began her career at a Big Four accounting firm and later advanced her professional expertise by earning her ACA qualification with a respected local firm.

Her professional journey is rooted in auditing, where she developed expertise working with a diverse portfolio of audit and non-audit clients across various industries. Ashley’s experience spans from supporting SMEs to managing large international group consolidations, giving her a comprehensive understanding of financial management across different business scales.

Ashley has been closely involved with the company’s accounts for several years via outsourced accountants, providing her with deep familiarity with its operations. Now, as Group CFO and Company Secretary, she is poised to leverage her extensive knowledge to drive strategic financial growth and ensure robust fiscal management.

Dr Sébastien R. Goudreau Ph.D.

Chief Scientific Officer

Born in Sherbrooke, Québec, Canada, Dr Goudreau obtained his PhD in Chemistry at the Université of Montréal as a NSERC fellow before moving to Switzerland to conduct postdoctoral studies at the ETH Zürich as an FRQNT fellow. He then moved back to Canada for one year where he co-founded FindMolecule inc. and worked for the pharma industry.

In 2014 he joined ImmuPharma as research director and established the research laboratories of Ureka in Bordeaux. After the merger of ELRO with Ureka in 2019, Dr Goudreau became Chief Scientific Officer of Ureka Pharma and in 2021, he became Chief Executive Officer of ImmuPharma Biotech. Notably, Dr Goudreau and his team are credited for the discovery and development of, among others, URK 614, BioGlucagon, and BioAMB.

Tim McCarthy FCCA, MBA

Chief Executive Officer

Tim has 40 years’ international senior level business experience in high growth biotech, healthcare and technology companies. He is also Chairman of Incanthera plc. Tim was formerly Chairman of 4basebio plc and CEO and CFO of a number of UK public listed and private companies including, Alizyme plc and Peptide Therapeutics Group plc, and has a core understanding of AIM and its regulatory processes. Co-founding a number of healthcare and biotechnology companies, he has helped raise substantial amounts of equity capital and also advised and worked at Board level for a diverse range of companies internationally, in areas such as business strategy, mergers & acquisitions, due diligence and licensing.